RAS like family 10 member BGenealiases: RRP17 · VTS58635
Q-omics provides the consensus-scored RASL10B profile across patient tissues and cancer cell-line models. RASL10B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RASL10B is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, RASL10B RNA expression shows 17,804 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where RASL10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASL10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASL10B survival associations across molecular data types. RASL10B RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASL10B RNA expression–survival associations across cancer types. High RASL10B expression shows unfavorable associations in ACC, KIRP, UCEC, MESO, BLCA and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RASL10B RNA expression.
This table summarizes RASL10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RASL10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASL10B shows lower tumor expression in KICH, KIRC and BRCA and higher tumor expression in COAD, LUAD and LUSC. The COAD box plot shows higher RASL10B RNA expression in tumor versus normal tissue (log2 FC = +0.888, t-test p < 0.001).
This table shows molecular features associated with RASL10B in patient tissues and cancer cell lines. In patient samples, RASL10B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RASL10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
